Sable Therapeutics Announces Exclusive Worldwide Licensing Agreement with Columbia University to Develop Novel Polycation Nanomedicines for the Treatment of Obesity ...Middle East

Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement with Columbia University NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Sable Therapeutics, an innovative early stage drug development company focused on pioneering fat reduction therapies, today...

Hence then, the article about sable therapeutics announces exclusive worldwide licensing agreement with columbia university to develop novel polycation nanomedicines for the treatment of obesity was published today ( Friday 09/08/2024 - 09:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sable Therapeutics Announces Exclusive Worldwide Licensing Agreement with Columbia University to Develop Novel Polycation Nanomedicines for the Treatment of Obesity )

Also on site :

• Protesters in Iraq swarm Kuwaiti consulate after deadly rocket attack
• What we know about the shooting by Istanbul’s Israeli consulate
• Donald Trump Just Gave California Democrats a Big, Fat Gift